Feed CLNN
CL

Clene Inc.

CLNN · NASDAQ

$3.92 +1.29% (+$0.05)
1M +8.29%
Market Cap $50.1M
P/E Ratio -
Div. Yield -
ROE -
Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 254.27x
EV/EBITDA N/A
P/B N/A
Growth
0 /100
Declining
Rev. growth 24.94%
FCF growth N/A
Book val. growth N/A
Profitability
0 /100
Weak
Net margin 20,059.90%
Op. margin 10,304.60%
FCF margin 8,103.50%
Quality
0 /100
Poor
ROA 171.51%
Asset turnover 0.01x
ROIC 104.55%
Debt
43 /100
Moderate
Int. coverage -10.15x
Current ratio 3.07x
Net debt/EBITDA N/A
Stability
24 /100
Unstable
Rev. volatility 47.95%
EPS volatility 85.50%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o CLNN
Online

O podjetju

Clene Inc. (CLNN) is a biotechnology company focusing on the development and commercialization of therapeutic therapies based on nanotechnologies for the treatment of neurodegenerative diseases. The company concentrates on developing therapeutic products that utilize nanocrystalline platforms to support nerve cell recovery and protection from degeneration. Clene Inc. is engaged in addressing diseases like amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. With the growing awareness of the need for neurodegenerative disease treatment, Clene Inc. has the potential for sustained growth. Clene Inc. (CLNN) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for neurodegenerative diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Robert Etherington

Employees

78

Headquarters

Salt Lake City

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

35d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.